NCT05697198 (PREFER) is a clinical trial of OmniSeq Test in Lung Cancer, sponsored by Labcorp Corporation of America Holdings, Inc.

Who is sponsoring NCT05697198?

NCT05697198 is sponsored by Labcorp Corporation of America Holdings, Inc.

What drugs are being tested in NCT05697198?

Interventions in NCT05697198: OmniSeq Test.

What condition does NCT05697198 study?

NCT05697198 studies Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer.

Is NCT05697198 still recruiting?

NCT05697198 is currently completed. Last updated 6 March 2025.

Last reviewed 2025-03-06 · How we verify

NCT05697198: PREFER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

Completed Last updated 6 March 2025

What this trial tests

trial testing OmniSeq Test in Lung Cancer in 1,429 participants. Completed in 31 December 2024.

Timeline

19 April 2021

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Labcorp Corporation of America Holdings, Inc
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,429
Start date	19 April 2021
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	8 locations across United States

Drugs / interventions tested

OmniSeq Test

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Ovarian Cancer — all drugs for Ovarian Cancer →
Uterine Cancer — all drugs for Uterine Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Labcorp Corporation of America Holdings, Inc

Who can join

18 and older, any sex, with Lung Cancer or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next generation sequencing of time-matched or archival tissue specimens from individuals with advanced solid tumors. Examples of locally advanced and metastatic tumors include stage III and IV cancers (ex. lung, breast, all gastrointestinal malignancies, all gynecologic malignancies, prostate cancer, head and neck tumors, soft tissue cancers, and melanoma). These specimens will be analyzed for diagnostic purposes and research (either by Labcorp/OmniSeq or to a third-party recipient designated by Labcorp/OmniSeq). Labcorp/OmniSeq may transfer the specimens and data to its clients, including commercial, academic or non-profit research institutions; or alternatively, may retain the specimens in its repository for future research use at the sole discretion of Labcorp/OmniSeq and or assignees. Labcorp/OmniSeq will maintain all detailed clinical information including demographic data (de-identified), ethnicity, disease state, stage (radiological, pathological and clinical-whichever is relevant).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care.
Sindhu KK, Dovey Z, Thompson M, Nehlsen AD, et al · · 2024 · cited 2× · PMID 38633827 · DOI 10.1002/bco2.323
Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.
Garcia-Pelaez J, Yáñez Y, Aupí M, Lázaro M, et al · · 2026 · PMID 42194957 · DOI 10.3390/genes17050500

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05697198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Labcorp Corporation of America Holdings, Inc
Last refreshed: 6 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05697198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing